Familial amyotrophic lateral sclerosis (ALS) is an inherited form of a devastating neurodegenerative disease that affects motor neurons in the brain and spinal cord. While only about 5 to 10 percent of all ALS cases are familial, understanding the genetic causes has opened new doors for targeted treatments, including gene therapies that were once only a distant hope.

How Treatment Approaches Are Changing Lives

Treating familial amyotrophic lateral sclerosis focuses on slowing the disease’s progression, managing symptoms, and maintaining quality of life for as long as possible. Unlike many conditions where a single treatment can reverse the disease, ALS requires a comprehensive approach that combines medications, supportive therapies, and emerging genetic treatments. The treatment plan varies significantly depending on which genetic mutation causes the disease, how rapidly symptoms progress, and the individual patient’s overall health and preferences.^[1]

Treatment goals center on helping patients maintain independence, manage muscle weakness and breathing difficulties, support nutrition when swallowing becomes difficult, and preserve the ability to communicate. Because familial ALS often develops earlier than sporadic cases—typically in the 40s or 50s rather than the 60s—early intervention becomes especially important. The discovery of specific genes linked to familial ALS has transformed how doctors approach treatment, making it possible to target the underlying genetic causes rather than just treating symptoms.^[5]

Medical societies and clinical guidelines now recognize that familial ALS requires both standard symptomatic treatments used for all ALS patients and specialized genetic therapies when available. Research into new therapies continues at an unprecedented pace, with clinical trials testing innovative approaches that could change outcomes for future generations. While there is no cure, the treatment landscape has evolved dramatically, offering more hope than ever before.^[6]

Standard Medical Treatments for Familial ALS

Standard treatment for familial ALS includes medications approved for all forms of ALS, regardless of genetic cause. Riluzole is the first medication approved for ALS and works by reducing levels of glutamate, a chemical messenger in the brain that can damage motor neurons when present in excessive amounts. This medication can extend survival by several months and is typically taken twice daily as a pill. Riluzole may cause side effects including fatigue, nausea, liver enzyme elevation, and dizziness, requiring regular blood tests to monitor liver function.^[2]

Another medication called edaravone acts as an antioxidant, helping to reduce oxidative stress—damage caused by harmful molecules called free radicals that accumulate in motor neurons. Edaravone is given through intravenous infusion, typically in cycles of daily infusions for two weeks, followed by a break. Clinical trials showed it could slow functional decline in some patients, particularly those in earlier disease stages. Common side effects include bruising at the infusion site, walking difficulties, and headaches.^[11]

Beyond these disease-modifying drugs, standard care includes numerous supportive treatments. Physical therapy helps maintain muscle strength and flexibility for as long as possible, while occupational therapy focuses on adapting the home environment and teaching techniques to conserve energy during daily activities. Speech therapy addresses communication difficulties and swallowing problems, which are common as the disease progresses. When swallowing becomes too difficult or dangerous, doctors may recommend a feeding tube to ensure adequate nutrition and prevent aspiration pneumonia.^[13]

Respiratory support becomes critical as the muscles controlling breathing weaken. Non-invasive ventilation, using a mask to help with breathing, can significantly improve quality of life and extend survival. Eventually, some patients choose more invasive mechanical ventilation through a tracheostomy, where a tube is placed directly into the windpipe. These decisions require careful discussion with the medical team and family members about goals of care and quality of life considerations.^[14]

Medications to manage specific symptoms play an important role throughout the disease course. Muscle cramps and stiffness can be treated with muscle relaxants, while medications for excessive saliva production help prevent choking and aspiration. Depression and anxiety are common in ALS and respond well to antidepressants and counseling. Pain management, though ALS itself doesn’t typically cause pain, becomes necessary when immobility leads to pressure sores or muscle stiffness causes discomfort.^[15]

The duration and intensity of these treatments evolve as the disease progresses. Regular monitoring through clinic visits every three to six months allows the medical team to adjust medications, introduce new supportive measures, and address emerging complications. This comprehensive, multidisciplinary approach has been shown to improve both length and quality of life in ALS patients, making specialized ALS clinics the gold standard for care.^[16]

Breakthrough Gene Therapies in Clinical Trials

The most exciting developments in familial ALS treatment involve gene therapies that target specific genetic mutations causing the disease. The success of gene therapy in spinal muscular atrophy, another motor neuron disease, demonstrated that targeting the genetic root of motor neuron diseases is not only possible but can be remarkably effective. This breakthrough has triggered a paradigm shift in developing ALS therapies, moving from symptom management to addressing underlying genetic causes.^[10]

The first gene therapy approved for familial ALS targets mutations in the SOD1 gene, which accounts for 13 to 20 percent of familial ALS cases. The SOD1 gene normally produces an enzyme called superoxide dismutase 1, which protects cells from damage. However, mutations create a toxic, misfolded version of this protein that accumulates in motor neurons, disrupting cellular processes and causing progressive damage. Understanding this mechanism opened the door to developing targeted treatments.^[6]

In April 2023, the medication tofersen, marketed as Qalsody, received accelerated approval from the FDA specifically for treating SOD1-linked ALS. Tofersen is an antisense oligonucleotide (ASO), a type of precision therapy designed to modify the expression of specific genes. This medication works by binding to both normal and mutated SOD1 messenger RNA, the molecular instructions that cells use to make proteins. By binding to this RNA, tofersen prevents it from being translated into protein, thereby reducing overall levels of SOD1 protein, including the toxic mutated form.^[6]

Tofersen is administered through injection directly into the spinal fluid surrounding the brain and spinal cord, a procedure called intrathecal injection. The initial treatment involves loading doses given every two weeks for three doses, followed by maintenance doses once every four weeks. In clinical trials, tofersen demonstrated the ability to reduce levels of the toxic SOD1 protein and lower levels of neurofilament light chain, a marker of neuronal injury. While the phase 3 trial did not show significant slowing of disease progression during the 28-week study period, doctors treating patients with tofersen report that benefits may take more than six months to become apparent.^[8]

Clinical experience suggests that tofersen may be most effective in patients with mutations associated with very aggressive disease, particularly when started early. Some experts believe the drug works best in people who have SOD1 mutations but do not yet show symptoms of the disease. A new trial called ATLAS is currently enrolling these pre-symptomatic carriers of SOD1 mutations to test whether preventing the disease from starting is more effective than treating it after symptoms appear. Currently, tofersen is only available to pre-symptomatic individuals through this clinical trial.^[8]

Other gene therapies are in development for different genetic forms of familial ALS. The C9orf72 gene mutation is the most common genetic cause of ALS in Europe and the United States, though it’s less common in Japan where SOD1 and FUS mutations predominate. This geographic variation means that the target mutations for gene therapy vary by ethnicity, and successful treatment strategies may need to be tailored to different populations. Researchers are developing ASO therapies for C9orf72 mutations, which involve abnormal repetition of a genetic sequence rather than a single point mutation.^[10]

The FUS gene and TARDBP gene (which produces the TDP-43 protein) are also targets for gene therapy development. TDP-43 pathology is particularly important because abnormal accumulation of misfolded TDP-43 protein occurs in over 95 percent of sporadic ALS cases as well as many familial cases. This has led researchers to investigate whether therapies targeting TDP-43 might have broader applications beyond just familial cases with TARDBP mutations. Clinical trials are in early phases, testing both safety and the ability to reduce toxic protein levels.^[2]

Phase I clinical trials focus primarily on safety, determining appropriate dosing and identifying potential side effects in small groups of patients. Phase I studies of various ASO therapies for ALS have generally shown acceptable safety profiles, with the main concerns being related to the intrathecal injection procedure itself rather than the medications. Phase II trials evaluate efficacy, measuring whether the treatment actually affects disease progression and relevant biological markers. These trials enroll larger groups of patients with confirmed genetic mutations and typically last six months to a year. Phase II studies of tofersen and other ASO therapies have demonstrated the ability to reduce toxic protein levels, providing biological evidence of drug activity.^[9]

Phase III trials compare new treatments with standard care in larger, randomized studies designed to prove clinical benefit. The challenge with ALS clinical trials is that the disease progresses at different rates in different people, making it difficult to demonstrate benefit in short study periods. This is why tofersen received accelerated approval based on biomarker evidence rather than waiting for definitive proof of slowed progression. The FDA required additional confirmatory studies to maintain approval, and longer-term data is now being collected to demonstrate sustained clinical benefits.^[9]

Many clinical trials for familial ALS are conducted at specialized ALS centers in the United States, Europe, and increasingly in Asia. In the United States, major medical centers including those at Northwestern University, Columbia University, and other academic institutions participate in these trials. Patient eligibility depends on having a confirmed genetic mutation that matches the therapy being tested, meeting specific disease stage criteria, and being able to travel to the trial site for regular assessments and treatments. Some trials enroll only symptomatic patients while others specifically seek pre-symptomatic mutation carriers.^[10]

Beyond ASO therapies, researchers are exploring other innovative approaches including gene replacement therapy, where functional copies of affected genes are delivered to motor neurons using modified viruses as delivery vehicles. Other strategies under investigation include therapies to enhance protein clearance, removing toxic proteins before they accumulate, and approaches to protect motor neurons from the cascade of damage triggered by genetic mutations. These remain in earlier stages of development but represent promising future directions.^[10]

Most Common Treatment Methods

• Disease-Modifying Medications
  • Riluzole reduces glutamate levels to protect motor neurons and may extend survival by several months
  • Edaravone acts as an antioxidant to reduce oxidative stress and slow functional decline in early-stage patients
  • Both medications require regular monitoring for side effects and liver function
• Gene Therapy
  • Tofersen (Qalsody) is an antisense oligonucleotide approved for SOD1-linked familial ALS
  • Administered through intrathecal injection into spinal fluid
  • Reduces toxic SOD1 protein levels and markers of neuronal injury
  • Most effective when started early in disease course or before symptoms appear
  • Other gene therapies in development target C9orf72, FUS, and TARDBP mutations
• Respiratory Support
  • Non-invasive ventilation using masks to assist breathing as respiratory muscles weaken
  • Mechanical ventilation through tracheostomy for advanced respiratory failure
  • Significantly improves quality of life and extends survival
• Nutritional Support
  • Feeding tube placement when swallowing becomes difficult or dangerous
  • Prevents malnutrition and aspiration pneumonia
  • Nutritional counseling to maintain adequate caloric intake
• Rehabilitation Therapies
  • Physical therapy maintains muscle strength and flexibility
  • Occupational therapy adapts home environment and teaches energy conservation
  • Speech therapy addresses communication and swallowing difficulties
  • Regular sessions throughout disease course adapt to changing needs
• Symptom Management
  • Muscle relaxants for cramps and spasticity
  • Medications to reduce excessive saliva production
  • Antidepressants for depression and anxiety
  • Pain medications for discomfort related to immobility
• Multidisciplinary Care
  • Specialized ALS clinics coordinate comprehensive care
  • Regular monitoring every three to six months
  • Care team includes neurologists, respiratory specialists, nutritionists, therapists, and social workers
  • Improves both length and quality of life